News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
Kelly Meza: Embracing new experiences this year
Kelly Meza/LinkedIn
Jan 2, 2025, 20:36

Kelly Meza: Embracing new experiences this year

Kelly Meza, Research Assistant at Dana-Farber Cancer Institute, shared a post on X:

“Embracing new experiences this year, surrounded by inspiring mentors, colleagues, and friends.

Grateful for the MedTwitter and Florez Lab family.

Feeling blessed to be in a field where we can truly make a difference.

Wishing you all a beautiful year ahead.”

Kelly Meza

cancer Florez Lab Kelly Meza MedTwitter OncoDaily Oncology
Special Coverage
Insight
Jan 31, 2025, 19:25
Tanja Obradovic: New Phase III trial with an innovative MOA may soon change the standard of care for second-line MSS CRC
Blog
Jan 31, 2025, 18:05
Shining a light on the EU-funded projects - Association of European Cancer Leagues
Blog
Jan 31, 2025, 17:28
Erman Akkus: Stage-specific characterization of “early-onset colorectal cancer”
Blog
Jan 31, 2025, 17:24
Shweta Bansal: Discussing complex cases like Neuroblastoma with global experts
Blog
Jan 31, 2025, 17:20
Razelle Kurzrock: Have you tried getting through CVS AI assistant?
Blog
Jan 31, 2025, 17:16
Michelle Kirschner: The Cancer Survivorship Provider Network is Launching an 'Ask The Expert' Series
Blog
Jan 31, 2025, 17:13
IASLC- Lung Cancer in Mexico: Perspectives from the North and Ciudad de Mexico
Blog
Jan 31, 2025, 17:09
Anna A. Avagyan: Grateful for an Incredible Learning Experience at Princess Máxima Center
Blog
Jan 31, 2025, 17:03
Submit your proposal to take part in this year’s London Global Cancer Week
Blog
Jan 31, 2025, 16:49
Karen Knudsen: Ka ʻUmeke Lama Initiative to Transform Cancer Care and Reduce Health Disparities in Hawai'i and the Pacific
Blog
Jan 31, 2025, 16:44
The importance of QOL and PRO in clinical research by Massimo Di Maio
Opinion
Jan 31, 2025, 16:37
Lauren Kriger Groner: Once again showing USPSTF Lung Cancer Screening criteria are inadequate